Monitoring heart failure
An in vitro method for identifying subjects at risk of heart failure following a Myocardial Infarction comprising analyzing the concentration of Matrix Metalloproteinase-9 in a bodily sample from a subject who has suffered a Myocardial Infarction and comparing this concentration with a reference for concentrations of Matrix Metalloproteinase-9 in individuals who have not suffered a Myocardial Infarction; wherein a raised concentration of Matrix Metalloproteinase-9 in the bodily sample from a subject who has suffered a Myocardial Infarction suggests the subject is at risk of heart failure.
1. An in vitro method for identifying a relative risk of heart failure in a subject following a Myocardial Infarction compared to subjects who have not suffered a Myocardial Infarction, the method comprising:
determining a concentration of Matrix Metalloproteinase-9 in a bodily fluid sample from a subject who has suffered a Myocardial Infarction wherein said concentration of Matrix Metalloproteinase-9 is determined within twenty-four hours of said Myocardial Infarction;
comparing the concentration of Matrix Metalloproteinase-9 in said subject following Myocardial Infarction with a reference concentration of Matrix Metalloproteinase-9 from individuals who have not suffered a Myocardial Infarction; and,
correlating the concentration of Matrix Metalloproteinase-9 to a relative likelihood of heart failure wherein the concentration of Matrix Metalloproteinase-9 in the subject's sample is predictive for the relative risk that the subject will develop heart failure two years following Myocardial Infarction.
2. The method according to claim 1 , wherein the sample is a blood sample or a urine sample.
3. The method according to claim 2 , wherein the blood or urine sample is analysed immediately after it is taken from the subject.
4. The method according to claim 2 , wherein the blood or urine sample is frozen and stored before being defrosted and analysed.
5. The method according to claim 1 , wherein the concentration of Matrix Metalloproteinase-9 is measured by zymography.
6. The method according to claim 5 , wherein the zymography comprises an electrophoresis step, a gel treatment step, and a staining step.
7. The method according to claim 1 , wherein the concentration of Matrix Metalloproteinase-9 is measured by zymography and densitometry.
8. The method according to claim 1 , wherein the concentration of Matrix Metalloproteinase-9 is measured by an enzyme-linked immunosorbent assay (ELISA), fluorometric assay, a chemiluminescent assay, or a radioimmunoassay.
9. The method according to claim 1 , wherein the sample is a blood sample and wherein the raised concentration of Matrix Metalloproteinase-9 is higher than 30 ng/ml or 200 pixels 2 .
10. A kit for identifying a subject's relative risk of developing heart failure following a Myocardial Infarction, the kit comprising:
(i) means for determining a concentration of Matrix Metalloproteinase-9 in a bodily fluid sample from a subject who has suffered a Myocardial Infarction; and,
a risk calculator that calculates the subject's relative risk of developing heart failure two years following Myocardial Infarction based upon the concentration of Matrix Metalloproteinase-9 in a bodily fluid sample from the subject.